Gene Editing in Mammalian Cells by Flp Recombinase Variants by Li, Feng
Louisiana Tech University 
Louisiana Tech Digital Commons 
Doctoral Dissertations Graduate School 
Spring 5-2020 
Gene Editing in Mammalian Cells by Flp Recombinase Variants 
Feng Li 
Follow this and additional works at: https://digitalcommons.latech.edu/dissertations 
   
 
GENE EDITING IN MAMMALIAN CELLS BY 
FLP RECOMBINASE VARIANTS 
 
by 












A Dissertation Presented in Partial Fulfillment 
of the Requirements of the Degree 










COLLEGE OF APPLIED AND NATURAL SCIENCES   































In this dissertation, DNA recombinase Flp modified variants were developed for 
gene editing. The Flp recombinases can perform recombination reactions to modify the 
DNA sequence on the Flp recombination target (FRT). The Flp can recognize the DNA 
sequences，which resemble the wild-type FRT when modified. The Flp modified 
variants show potential values for genomic engineering because such FRT-like sequences 
as targets are widespread in the human genome. Our goal is to evolve the Flp variants on 
FRT-like targets in the human genome for safety and efficiency, correcting the genome 
mutations which cause the genetic disease. 
Gene editing relies on site specificity nucleases such as transcription activator-like 
effectors nuclease (TALEn), Zinc finger nuclease, or CRISPR/Cas9. Flp, as a site 
specificity recombinase has different mechanisms on the DNA modification. The 
recombinases do not cut the DNA by removing the fragment as nucleases and show better 
safety in gene modification. That's the reason we chose site specific recombinases as our 
research target. 
We chose the FRT-like sequences in the human interleukin gene and beta 
hemoglobin gene as our target for Flp evolving. To improve the specific activity of these 
Flp variants on targeted FRT-like sequences in human cells, DNA-binding domain from 
transcription activator-like effectors (TALE) which are found in the plant pathogen 
Xanthomonas were fused to the Flp variants, to form Flp-TAL variants. The DNA-
iv 
binding domain from TALE can be programmed to recognize the designated DNA 
sequence and improve the specificity binding of the nearby working domain. 
The Flp-TAL variants have been proven able to perform DNA recombination in 
human cells. My work concerns evolving Flp-TAL variants to recombine the FRT like 
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Genome manipulation at desired locations opens an opportunity to develop model 
cells, model organisms, and to correct genetic disorders. Recent advances in the 
developing field of genome engineering are primarily attributed to site-specific DNA 
nucleases: mainly zinc finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs), and nucleases that are based on the clustered regularly interspaced 
short palindromic repeats/Cas9 systems (CRISPR/Cas9) (e. a. Cong L 2013, e. a. Miller 
JC 2011). However, several inherent properties of site-specific nucleases, which include 
the very necessary to introduce double strand breaks and the reliance on the cell’s DNA 
repair machinery to process these breaks, prompted the researchers to look for other 
genome engineering systems that utilize different DNA manipulation mechanisms. Apart 
from converting CRISPR/Cas9 into site-specific deaminases (Komor AC 2016, Kim YB 
2017), site-specific tyrosine and serine DNA recombinases are attractive alternatives 
(Grindley, Whiteson and Rice 2006). 
The burst of the nuclease-based genome engineering applications is triggered by 
two main factors: the efficiency of cleavage of genomic targets by these composite 
nucleases and the relative ease with which their target recognition units can be 
assembled, especially for the CRISPR/Cas9-based systems. Although site-specific 
nucleases can locate and cleave their targets, these enzymes are not able to complete the 
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genome modification task: the host DNA repair machinery is required to seal the 
introduced DNA breaks either by the non-homologous end joining (NHEJ) or by the 
homologous DNA repair mechanisms. 
Compared to site-specific nucleases, other genome manipulation tools, the site-
specific DNA recombinases do not generate double strand breaks in DNA and can 
accomplish the genome modification task without any assistance from the host DNA 
repair machineries. Popular site-specific recombination systems employed for genome 
engineering applications include Cre/lox from coliphage P1, Flp/FRT from 2 micron 
plasmid of S. cerevisiae, and φC31/att from Streptomyces phage φC31.  
Tyrosine recombinases, such as popular genome engineering tools Flp and Cre, are 
highly specific for their targets, versatile in performing DNA manipulation reactions and 
can be easily regulated. However, the native recombinase can only be useful for genome 
engineering if the native targets for tyrosine recombinases are pre-introduced into a 
genome locale of interest. This makes it impossible to utilize the original tyrosine 
recombinases in the applications that are aimed to manipulate the genome in unmodified 
cells. 
Fortunately, the recombinase variants which utilize genomic sequences resembling 
native recombination targets can be evolved (Buchholz F 2001, Sarkar I 2007, e. a. 
Bolusani S 2006, Shultz JL 2011). The total number of target-like sequences in a genome 
can be quite substantial: the human genome, for example, has about 600,000 of the FRT-
like sequences that have different levels of homology to FRT, the native recombination 
target for Flp recombinase. This number corresponds to one FRT-like sequence per 5 kb – 
such density allows DNA manipulations essentially in all genomic locations provided the 
3 
variants that are evolved to recombine with these sequences can bind them in their native 
chromosomal environment, outcompeting other DNA binding proteins, primarily histones. 
It appears that tyrosine recombinases lack the well-defined DNA binding motifs with 
clear rules that specify which residues need to be mutated to achieve the target specificity 
switch (Guo, Gopaul and van Duyne 1997, Chen, et al 2000). Moreover, the entire structure 
of tyrosine recombinases seems to take part in the functional target recognition (Buchholz 
F 2001, e. a. Bolusani S 2006). Such a mode of protein-DNA binding restricts the evolution 
process of the target-specific tyrosine recombinase variants to mainly random target-linked 
mutagenesis although the modification of the residues that participate in the protein-DNA 
recognition can speed up the evolution process (Buchholz F 2001, Sarkar I 2007, e. a. 
Bolusani S 2006, Shultz JL 2011, Karpinski J 2016, L. F. Shah R 2015). 
Instead of applying protein evolution, a different approach was used to engineer target-
specific variants of tyrosine recombinases that have two domains with distinct functions: 
target binding and catalyzing (Grindley, Whiteson and Rice 2006). In this approach, a 
modified catalytic domain with relaxed target specificity is fused with the DNA binding 
domain, target specificity which can be easily programmed. This approach was 
successfully applied to create different hybrid tyrosine recombinases, such as zinc-finger 
recombinases (ZFRs), TALE recombinases,(TALERs), and Cas9 recombinases(recCas9).  
Each of these was created by fusing the activated catalytic domains of the invertase Gin or 
the resolvase Tn3 with the DNA binding domains of either zinc fingers, TAL effectors, or 
the catalytically inactive Cas9 protein, respectively (Akopian A 2003, Gordley RM 2007, 
Mercer AC 2012, Chaikind B 2016). 
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This modular design concept when proteins with different functional properties are 
fused together was also successfully applied to develop hybrid site-specific nucleases: zinc 
finger nucleases, or ZFNs, and transcription activator-like effector nucleases, or TALENs, 
that are composed of a nonspecific DNA nuclease FokI and the respective DNA binding 
domains with programmable target specificity (Kim YG 1996, Christian M 2010). Target 
affinity and specificity in these modular systems can be modified by changing the number 
of the target recognizing units in their DNA binding domains to achieve the optimal 
balance between target specificity and non-specific DNA binding (e. a. Miller JC 2011, 
Carroll and Porteus 2005, Urnov FD 2005, e. a. Miller JC 2007, Cermak T 2011, Gaj T 
2013). 
The modular design can be applied to develop hybrid tyrosine recombinases that would 
benefit from additional target-specific DNA binding domains which can stabilize the 
recombinase variants on their targets, thus increasing their activity. In principle, two classes 
of the hybrid tyrosine recombinases can be developed that will differ at the level of target 
specificity of their recombinase modules. In the first class, both modules of the hybrid 
enzyme – the tyrosine recombinase variant and the extra DNA binding domain – can be 
evolved or engineered to be specific for a particular genomic target sequence of interest. 
As such, this class of the hybrid tyrosine recombinases can be the most target specific 
genome engineering tool available, but the modification of the target specificity of their 
recombinase module can require an effort. 
In the second class of the hybrid tyrosine recombinases, the two modules differ at the 
level of their target specificity: the recombinase module can be evolved to have broad 
specificity toward genomic target sequences while the extra DNA module can be 
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engineered to deliver this recombinase module to a particular target-like sequence where 
the recombination reaction will take place. The recombinase module in these hybrid 
recombinases should be relatively weak to reduce the probability of recombination of the 
genomic target sequences on its own, thus preventing abnormal recombination events. 
However, the recombination activity of this weak module should be stimulated upon 
binding to the desired target sequence due to the target binding stabilization by the extra 
DNA binding domain. Since the target specificity of the recombinase module can be made 
broad, this module can be used to generate hybrid recombinases of different target 
specificity simply by changing the target specificity of the extra DNA binding module. As 
such, in contrast to the hybrid tyrosine of the first class, the effort to modify the target 
specificity of the hybrid tyrosine recombinases of the second class will be relatively low. 
In this work we analyzed the suitability of both classes of the hybrid tyrosine 
recombinases for genome engineering. For this, we developed Flp-TAL recombinases, 
which are composed of a variant of Flp recombinase with either narrow or broad target 
specificity that are fused with the DNA binding domain of the TAL effectors (TAL DBD). 
Using a simplified protein evolution approach, the Flp variants for Flp-TAL were evolved 
to recognize FRT-like sequences in the human β-globin gene. We examined the integration 
and deletion activity of the Flp-TAL recombinases in intact human HEK293 cells and 
found that only the hybrid Flp-TAL variants but not the respective target-specific Flp 
variants were able to efficiently perform these reactions. We also demonstrated that the Flp 
variant with broad specificity toward FRT-like sequences can be indeed fused to TAL 
DBDs of different target specificity to direct the variant to new genomic target sequences. 
We estimated that the efficiency of the integration and deletion reactions mediated by the 
6 
Flp-TAL variants is about 0.1% and 10% respectively, which is comparable to that of wild-
type Flp. Our results suggest that hybrid tyrosine recombinases can be developed into an 










Gene editing can be used to correct genetic mutations in the human genome 
which can cause genetic disease. The genetic diseases like common sickle cell disease 
(SCD) and neurofibromatosis (NF) are caused by a single gene mutation that may in 
future be cured by gene therapy. Since 1989, the first gene therapy was used in clinical 
experiments (Rosenberg SA 1990). Currently, the safety and efficiency of gene therapy 
has developed significantly, but it still has not met the expectations of clinical 
applications. Early on, gene therapies were more focused on delivering the exogenous 
genes to restore the proper biological function (Hanna, et al. 2017). The viral vectors, 
which were used as gene delivery vehicles in gene therapies, have a high probability of 
inserting vectors randomly in the genome. That situation does not just miss the target of 
gene therapy but also activates the tumor-promoting pathways in the cell. The research of 
gene therapy on severe combined immunodeficiency (SCID) had shown such a risk 
(Boudes 2014). 
An alternative treatment option for inherited monogenic diseases is correcting the 
gene mutation by gene editing on the cellular level, which may restore partial cellular 
function. When the cells restore the function, the functional cells are transferred to 
replace the malfunctioning ones to regain function.  
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My research aims to use site-specific Flp/FRT recombinase to correct the 
pathogenic mutation in mammalian cells. 
 
 
2.1 Site-specific recombinases 
Site-specific DNA recombinases can bind to specific DNA sequences called 
recombination targets and catalyze DNA rearrangement. With high-specificity and 
efficiency, site-specific DNA recombination has become an essential genomic 
engineering tool (Kilby, Snaith and Murray 1993). Site-specific recombinases can 
rearrange DNA sequences in several ways: integration/deletion, inversion, and 
replacement (Gibb B 2010) in bacteria, plant and human cells (Figure 2-1). By deletion, a 
small circular DNA fragment excised from the genome, or a circular DNA plasmid is 
severed into two small circular plasmids. The integration and excision are reversible 
processes while the recombination targets are still in the genome. In replacement, the 
gene cassette is exchanged between two different genomes. 
There are variants of site-specific recombinase working on identical DNA 
sequences from different origins that can be used as tools for gene editing (Stark 2014, 




2.2 Flp recombinase  
Flp, as a site-specific recombinase, was derived from the 2-micron plasmid of the 
baker's yeast Saccharomyces cerevisiae, and is part of a dual strategy system that 
maintains the plasmid's high copy number (Utatsu, et al 1987)(Figure 2-2). Flp 
recombinases can perform recombination without any accessory proteins in mammalian 








Figure 2-1 Three main types of DNA rearrangements catalyzed by site-specific 
recombinase: (A) deletion/integration, (B) inversion, (C) The gene/cassette replacement, 






Table 1 Examples of recombinases and their biological functions (6-9) 





Integration of the viral 
genome into the 
bacterial chromosome 




Escherichi coli Resolving chromosome 
and plasmid dimers 
Cre loxP bacteriophage P1 Circularization of linear 
phage genomes. 












Integration of the viral 





2.2.1 The mechanism of Flp recombination 
Flp is a member of the tyrosine family site-specific recombinases, which also 
include Cre, XerC/D, and λ-Integrases. This family name comes from the highly 
conserved tyrosine residue, which plays a key role in the recombination reaction. The 343 
tyrosine residue in the Flp is essential for the catalytic function, but does not contribute to 
substrate recognition (11).  
The tyrosine residue at position 343 in Flp attacks the DNA and links to it 
covalently during the strand exchanging stage in the recombination reactions. Flp-
mediated recombination begins with tetramerization of four Flp monomers to two FRT 
molecules; then a Holliday-junction intermediate is formed (Figure 2-3, Figure 2-4). 
Figure 2-2: The 2-micron plasmid of the yeast Saccharomyces cerevisiae and the Flp 
Recombination Target (FRT) sequence. (A) The 2-micron plasmid from which Flp is 
encoded also contains three genes (REP1, REP2, and D, which are not shown on the 
figure) that regulate the expression of Flp. When recombination occurs, two FRT 
sequences approach each other to make the plasmid dumbbell-shaped. The recombination 
relocates the genes on the plasmid and controls the expression of the REP1 gene, which 
controls the replication of the 2-micron plasmid. The 2-micron plasmid's copy number is 
controlled by such a Flp-FRT recombination system. (B) FRT is composed of two 13- 
based pair-inverted repeats, which bind to the recombinase, and an 8 base pair spacer. 
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After two strand cleavages occur, the Holliday intermediate is resolved. Later, the 
recombination products are released. 
 
Figure 2-3: Site-specific recombinase Holliday intermediate formation and resolution. 
DNA rearranges by building and resolving the Holliday construction in recombination. 
(A) The Flp and DNA form a tetramer and activate the recombination reaction. (B) DNA 
cleavage occurs in single-stranded DNA and forms a nick. (C) The first DNA exchange 
produces a Holliday intermediate. (D)The second DNA cleavage and exchange in 
Holliday intermediate. The purple arrows show where the DNA cleavage occurs. 




2.2.2 Recombinases can be used as tools for genome manipulation 
Recombinases can be used as tools for genome manipulation. However, the use of 
the Flp recombination system in genome engineering is limited because the native Flp 
can only recognize the wild-type FRT sequence. Thus, the wild-type FRT site has to be 
introduced into the genome before genomic manipulation is performed. 
As a tyrosine recombinase, Flp lacks a distinct DNA binding motif with clear 
rules that dictate which residues require mutations to achieve target-specific 
transformation (Guo F 1997, Chen Y 2000). Furthermore, the entire structure of tyrosine 
recombinase appears to be involved in functional target recognition (Buchholz F 2001)  . 
This protein-DNA binding pattern limits the evolution of target-specific tyrosine 
recombinase variants primarily by random target linked mutagenesis, although 
Figure 2-4: The 3D Holliday construction of the Flp and DNA (purple) tetramer.
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modification of residues involved in protein-DNA recognition accelerates evolutionary 
processes (Shultz JL 2011, Karpinski J 2016, L. F. Shah R 2015, Ingram 1957). 
However, the mutated, or evolved Flp variants can bind to an FRT-like sequence 
in the human genome. Modifying the different types of amino acid residues in Flp can 
alter or relax the target specificity of Flp, thus enabling the modified Flp variants to 
combine with the sequence, which can be called FRT-like sites (e. a. Bolusani S 2006, 
Voziyanov Y 2003). 
It has been proven that evolved Flp variants can be used as an efficient method of 
site-specific recombination in mammalian cells. In mammals, there are a large number of 
DNA sequences in the genome that are similar to the FRT-like sites. 
2.3 The selection of the target in human genome 
Several FRT-like sites in the human genome are identified through sequencing 
analysis by software. Some of the sites are selected as the targets of the research because 
of their location in the genome. The modified Flp variants, which can perform 
recombination reaction at these sites, can be used as genomic engineering tools with 
potential clinical value. 
2.3.1 The FRT-like sequence in the human interluekin gene 
We chose a FRT-like sequence in the human interleukin gene as one of our 
targets, and name it IL10A(Figure 2-5 B). 
2.3.2 The FRT-like sequence in the human δ-globin gene 
For our experiments, we chose three FRT-like sequences that are located upstream 
of the human δ-globin gene and within the δ-globin and β-globin genes: FL-61, FL-63, and 
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FL-71, respectively, which are separated from each other by 2.7 kb and ~7.5 kb, 
respectively (Figure 2-5 A and B). 
These FRT-like sequences, as well as other genomic FRT-like sequences, can have 
several potential upstream and downstream TAL recognition sequences since the 
requirements for the TAL recognition sequences are quite relaxed – the only major 
prerequisite is a thymine at the position N-1 of the sequence: 5’T (Lamb BM 2013). We 
reasoned that to be useful in targeting Flp-TAL recombinases to the desired FRT-like 
sequences and to be easily manageable from the technical point of view, the TAL module 
has to recognize the DNA sequence of 15-24 bp in length. We also reasoned that the TAL 
binding sequence should be separated from the recombinase binding element of the FRT-
like sequence by 3 to 12 base pairs to avoid steric clashes between the hybrid recombinase 
modules or their significant spatial separation. 
Additionally, we reasoned that the length of the TAL binding sequences should 
correlate with the degree of similarity between the Flp binding elements of the FRT-like 
sequence and that of FRT: the weaker the similarity, the longer the TAL recognition 
sequence. Based on the above considerations, we decided to test the TAL biding sequences 
of 15 bp in length (except for the upstream 24-bp TAL binding site for FL-71) that are 
separated from FL-61, FL-63, FL-71 by 4-5 bp (Figure 4- 2C). 
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2.4 Evolution of target-specific Flp variants 
2.4.1 Generation of Flp variant libraries 
We need a gene library that contains large mutations of Flp variants. However, in 
a laboratory environment, for a single functional protein, a large number of mutations can 
be accumulated in a short time by biochemical means, and screened to a specific target, 
so that the protein enhances a particular function and characteristics. In the past, artificial 
mutagens have been used extensively to achieve such a purpose. But now, with PCR 
methods, higher mutation efficiencies can be obtained to accumulate the gene library. 
Figure 2-5: FRT-like sequences FL-61, FL-63, FL-71 and FL-L10A. (A) Relative location 
of FL-61, FL-63, and FL-71 in the human beta globin genome. (B) Alignment of FRT, 
FL-61, FL-63, FL-71and FL-IL10A. The base pairs in FL-61, FL-63, FL-71and FL-
IL10A  that differ from the corresponding base pairs in FRT are shown as lower case bold 
black letters. (C) FL-61_TAL, FL-63_TAL, and FL-71_TAL sequences. 5’T bases for 
the TAL recognition sequences (marked by blue arrows) are shown in red. 
17 
The techniques for the directed evolution techniques include error prone PCR and DNA 
shuffling. 
2.4.1.1 Variants’ gene pools 
The Flp variants’ gene pools have been created by a method error-prone PCR. 
The error-prone PCR can introduce random mutations into the DNA sequence when 
amplifying DNA. The error-prone PCR can generate mutated gene libraries by controlled 
condition PCR. Leung first discovered the error-prone PCR in 1989 (Leung, Chen and 
Goeddel 1989). Cadwell and Joyce (Cadwell RC 1992) amended the protocol in 1992. 
The parameters altered in the PCR reaction can introduce random mutations in the gene 
fragment. 
In my experiments, the Flp mutant library was obtained via error-prone PCR 
performed by my laboratory colleagues and added to the FLP mutant variant  FL4. 
2.4.1.2 DNA shuffling 
DNA shuffling as a method can be used to generate a library of target genes with 
varying mutations for Flp variants (Shultz JL 2011). The mutated Flp DNA mixture will 
be treated with DNaseI. DNaseI can digest DNA into small fragments, and then 
reconstruct the DNA via PCR without additional primers (Figure 2-1). The enriched 
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mutated Flp variants library will be obtained.
 
2.4.1.3 Functional screening of Flp libraries in E.coli 
To pick up functional Flp variants, Flp variant libraries will be cloned into a 
selection plasmid, transformed into E.coli, and screened for variants with high activity 
and site-specificity for target sequences. The plasmid is based on a pBAD expression 
vector, which can control the expression level of Flp variants by adjusting the 
concentration of arabinose. The Flp variant libraries which can activate the recombination 
Figure 2-6: The shuffling of the Flp variants’ library. When digested by different 
concentrations of DNase I, the DNA sheared into small fragments (B, D). Different 
concentrations of DNase I will produce different sizes of DNA fragments. The DNA 
fragments of around 500 bps will be taken to run the assembling PCR. The DNA 
fragments will be assembled to their original size, which are about 1.5kb, the size of Flp 
variants’ sequences (C, E). Using primers for Flp variant sequences, the PCR can amplify 
the original size of Flp variants’ sequences with enriched mutations (C, F). M: 2-log 
ladder marker. 
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on the target sequences will change the construction of the plasmid. Both positive and 
negative selection can be used to select Flp variants (Figure 2-7). 
In positive selection, the Flp variants’ libraries that have recombination activity 
can be selected. In negative selection, the Flp variants’ libraries that have over activity on 
Figure 2-7:  The positive selection system (A) and the negative selection system (B).Flp 
variant libraries cloned into the positive selection system (A). Before the recombination, 
the primers (the red arrows in the picture) which combine on the lacZ gene are unable to 
amplify the DNA fragment by PCR. After expression, when the Flp variants expressed 
from the plasmid activate the recombination on the right target (FL-71), the LacZ part in 
the plasmid will be inverted. Using the primers that combine the LacZ part, the sequence 
that contains proper Flp variants’ sequence will be PCR amplified. In the negative 
selection system (B), when Flp variants activate the recombination on the wrong target 
(between FL-71 and other FRT-like sequence FRT-sp71, which has the spacer from FL-
71 and the recombinase binding sequences of FRT), the LacZ part in the plasmid will be 
deleted, and the primers that combine the LacZ part cannot amplify the over-active Flp 
variants. If the Flp variants are unable to activate the recombination on the FRT-sp71, the 
DNA fragment that contains the Flp variant sequence can be PCR amplified by the 
respective primers. 
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other FRT-like sequences will be screened out. In such a system, the Flp variants with 
both high recombination activity and site-specificity can be screened out. 
A color screening of the E.coli system will be used to identify Flp variants from 
the Flp variants’ libraries. This color screening system is also a negative selection system 
on solid bacterial culture. The Flp variants’ expression plasmid will be transformed into 
E.coli with a reporter plasmid, which contains the lacZ gene flanked by FRT-like sites. 
After correct recombination occurs, the lacZ gene will be deleted from the reporter 
plasmid. The deletion of lacZ can be observed by the color of colonies (Figure 2-8). Flp 
variants which perform correct recombination will be expressed in the white E. coli 
colonies. The white colonies can be picked, and the Flp variants can be obtained from 
those colonies. Flp variants obtained from the screening will re-pass the pathway of 




Figure 2-8: The Color selection system. The reporter plasmid (A), which contains 
the lacZ gene, can turn E.coli colonies blue color on the X-gal plate (B). When the 
Flp variant expression plasmid, which has been co-transformed with the reporter, 
performs a deletion recombination, the lacZ gene from the reporter plasmid will be 
deleted (lacZΔ), causing the colonies to turn white. When the plasmids are collected 
from the E.coli colonies, the size of the reporter plasmid can also show a difference 
from the deletion of the LacZ gene (D). 
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2.5 Testing of the target-specific Flp variants’ activity in eukaryotic cells 
We designed the following system to detect the activity of Flp variants in 
eukaryotic cell culture. 
2.5.1 Deletion assay in eukaryotic cells 
The deletion activity of Flp variants is significantly higher than integration 
activity. We test the deletion activity of the variants on episomal plasmid in eukaryotic 
cells. The variants will be cloned into a eukaryotic expression plasmid. The designed 
reporters can be used to check the recombination activity by the fluorescent color of the 
cells (Figure 2-9). Chinese hamster ovary (CHO) cells and human embryonic kidney 293 




Figure 2-9：The deletion reporter in the eukaryotic model cell. The reporter 
contains the EGFP gene, which is flanked by two FL-71 sequences that 
enable the cells to show green fluorescent color. When proper 
recombination occurs, the EGFP gene will be deleted by Flp variants. The 
CMV promoter will directly activate the DsRed gene, which causes the cells 
to show red fluorescent and to lose its green color. 
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2.5.2 Integration assay in eukaryotic cells 
In order to test the integration activity of the Flp variants in mammalian cells, the 
Flp variants will also be tested using the integration assay in eukaryotic model cell CHO 
(Chinese hamster ovary) or HEK 293 (Human Embryonic Kidney 293) cells. In 
integration assays, a designed color display reporter and a pre-modified model cell line 
will be used (Figure 2-10). In 48 hours, the color change will display whether correct 




Figure 2-10 The integration reporter in eukaryotic model cell. 
(A) A CMV promoter is located upstream of the FL-71 site in 
the coming reporter. In the mode cell genome, the platform 
reporter with FL-71 site and DsRed gene cannot express red 
color because of the lack of promoter. (B) When correct 
recombination occurs, the reporter will integrate into the cell 
genome, and the CMV promoter will activate the DsRed 




2.6 The development of  Flp-TAL variants 
2.6.1 TALE construction 
By fusing the target recognition units in the DNA binding domain from zinc 
finger nucleases, or ZFNs, and transcription activator-like effector nucleases, or 
TALENs, the target affinity and specificity of Flp variants can be modified to achieve an 
optimal balance between target-specific and non-specific DNA binding (Porteus MH 
2005, Urnov, et al 2005). 
To improve the specificity of Flp variants on target FRT-like sites, the Flp 
variants were fused to the designed domains. Transcription activator-like effectors 
(TALE) that are found in the plant pathogen Xanthomonas have a DNA-binding domain 
(DBD). A series of repeat 33-35 amino acid modules constructed these DBDs, which we 
called "TAL" domains. In each module, two adjacent repeat variable di-residues (RVDs) 
mediated the binding of a single nucleotide (Figure2- 11), There are  'NI' RVD codes for 
'A' DNA base, 'HD' for 'C', 'NG' for 'T' and 'NN' for 'G' DNA base. Changing the RVDs, 
TAL can be modified to bind the designed DNA sequence (Scholze H 2011, Mussolino C 
2012). Fusing the TAL to FokI nuclease has recently been achieved (Mussolino C 2012, 
Bedell, et al  2012), which gives the protein binding specificity for the designed DNA 
sequence. Thus, evolved Flp variants will be fused with TAL domains; they will have 




2.6.2 Flp-TAL variants 
In my experiments, the TAL RVD domain will be fused with selected Flp variants 
in the vector plasmid. TAL domains will be assembled using the Golden Gate TALEN 
Kit from Voytas Lab Golden described in Cermak et al. 2011 (Cermak T 2011). This Kit 
was designed for constructing TAL-linked nuclease FokI. The vectors from Golden Gate 
TALEN Kit were modified to link the TAL domain with Flp variants (Figure 2-12). The 
fused protein can be expressed and selected for recombination activity. For Flp variants 
which bind on their own targets, two different TAL domains will be designed for 
different binding regions. The Flp part will act as the catalytic domain, and the TAL 
module will serve as a DNA binding domain. 
Figure 2-11： The 3D model of TAL. The RVDs are specific to their targets， and the 
code of how they bind to a base pair has been solved. The RVDs can be easily engineered 
to bind specific DNA targets. (The figure is downloaded from (Osgood 2013) 
http://parts.igem.org/Part:BBa_K1189000 and modified). 
26 
Gene sequences with TAL targets can be added to the selection vector for e.coli 
or eukaryotic cells. In this way, the selection of FL variants can be made with the TAL 
domain or without it. We will compare the two methods in the experiment, which can 
produce variants that are more active. The activity of Flp-TAL variants will be tested in 
the same ways as Flp variants. 
 
Figure 2-12： Flp-TAL recombinases. (A) General mode of target binding by Flp-TAL 
recombinases. (B) Relative arrangements of the Flp and TAL recognition sequences 






3.1 The construction of the Flp variants’ libraries 
3.1.1 DNA shuffling 
The DNA shuffling method originated from Cadwell and Joyce (Cadwell RC 
1992). We researched this method and made extensive modifications for expanding the 
Flp variants’ library, ultimately creating our own protocol: 
1. The DNA fragment was treated with DNase I (Roche®) for analytical 
digestion: 
The activity of the enzyme DNase I (Roche®) varies with storage time. To obtain 
300-400 bp DNA fragments for shuffling, analytical digestion is required to determine 
the optimal conditions before digesting the DNA each time. 
The DNA fragment was digested with different concentrations of the DNase. 
DNA Tris MgCl2 DNase I 
1.5 µg 50 mM 10 nM 0.5 U 
1.5 µg 50 mM 10 nM 1 U 
1.5 µg 50 mM 10 nM 2 U 
1.5 µg 50 mM 10 nM 5 U 
1.5 µg 50 mM 10 nM 10 U 
1.5 µg 50 mM 10 nM 20 U 
The final volume of each reaction is 10µl. The reaction was placed on ice for 5 
minutes. Then it was heated to 80 degrees for ten minutes to stop the reaction. 
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The reaction productions were loaded on agar gel, and the electrophoresis was run 
to test the best conditions. 
2. DNase I digestion for shuffling 
The digestion was repeated under the best conditions, which made the DNA 
fragments most closed to 300-400 bp. The volume of each reaction was 50 µl. The 
reaction was placed on ice for 5 minutes. Then the reaction was stopped by adding the 
binding buffer from GeneJET Genomic DNA Purification Kit (Thermo Scientific™® 
K0721). 
The DNA reaction mixture was purified by GeneJET Genomic DNA Purification 
Kit (Thermo Scientific™® K0721). The results were checked by agarose gel 
electrophoresis. 







dNTPs Taq Total volume 
20µl 10µl 200 µM 2.5 Unit 100µl 







Thermocycling conditions for the PCR: 
Step Temp Time 
Initial Denaturation 94℃ 30'' 
40 Cycles 94℃ 30'' 
45℃ 1' 
72℃ 2' 
Final Extension 72℃ 10' 
Hold 4℃  
 
Check the PCR production with agar gel electrophoreses. 








Primer pair dNTPs Taq Total volume 









Thermocycling conditions for the PCR: 
Step Temp Time 
Initial Denaturation 94℃ 30'' 
23 Cycles 94℃ 30'' 
45℃ 1' 
72℃ 2' 
Final Extension 72℃ 10' 
Hold 4℃  
 
The PCR product was checked with agar gel electrophoresis. The product from 
the second round of PCR is in the Flp variants’ library. 
 
 
3.2 Bacterial Experiments  
All the bacterial experiments used the E.coli strain NEB 10-beta [araD139Δ(ara-
leu)7697 fhuA lacX74 galK (ϕ80Δ(lacZ)M15) mcrA galU recA1 endA1 nupG rpsL 
(StrR) Δ(mrr-hsdRMS-mcrBC)] from New England Biolabs® 
3.2.1 The construction of Flp expression vector  and reporter vector 
The plasmid used in this experiment was based on commercial plasmids. These 
commercial plasmids were purchased from the website Addgene (www.addgene.org). It 
was modified by PCR with specific primers and spliced by the restriction endonuclease. 
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PCR is a routine method. The restriction endonuclease was purchased from NEB(New 
England Biolabs®) and used its protocol. 
We subcloned the Flp variants into pBAD33 expression system from Thermo 
Fisher Scientific® as a Flp variant expression system. The expression of the Flp variants 
can be controlled by the concentration of the X-gal. The +/- liquid selection systems are 
also based on the pBAD33 plasmid. [Figure 2-2, Figure 2-3] 
Plasmids based on pBAD24 contain a lacZ gene flanked by two FRT-like 
sequences that will be used as reporter plasmids to detect the activity of Flp variants in 
solid bacterial culture screening. 
3.2.2 Preparation of the competent cell 
Both the expression and reporter vectors were transformed in E. coli bacterial 
strains. These strains were initially made competent using the p24 reporter plasmid and 
then used to transform expression plasmids to monitor activity and screening. 
3.2.3 The bacterial screening in liquid culture 
The ligation product of the inversion reporter and a Flp variant library were 
transformed into bacterial cells and incubated with the inducer L-arabinose at the final 
concentration 0.1% for 2.5 hours. Then, the transformed cells (0.3 ml) were transferred 
into 20 ml of LB supplemented with chloramphenicol (35 µg/ml) and incubated 
overnight. The reporter plasmids were then isolated and subjected to the PCR analysis to 
identify those Flp variants that were able to invert the reporter. 
3.2.4 The colony screening of  FLP variants in bacterial culture 
The deletion assays in E. coli were performed by the protocol form Voziyanov et 
al (Voziyanov, Stewart and Jayaram 2002). the Flp variant library expression vector 
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(pBAD33) was transformed into bacterial cells that harbored the deletion reporter 
(pBAD24 (27)). After incubating the transformed cells with the inducer L-arabinose at 
the final concentration 0.1% for 2.5 hours, the cells were plated onto LB/agar plates 
containing X-gal to visualize the colonies in which the deletion of the lacZα cassette 
occurred. 
Viable Flp variants screened from bacterial experiments will further eukaryotic 
cell experiments. 
3.3 Fusion with TAL Domain 
In the Flp-TAL design we utilized the TAL DNA-binding domain and the inter-
modular linker that were proven in other hybrid enzymes (Figure 1C). The full-size Flp 
recombinase variant was fused to the TAL core DNA-binding domain that starts at the 
position +152 (Δ152 truncation of the N-terminal segment of the TAL effector) and ends 
at the position +95 of the C-terminal segment of the TAL effector (1). The Flp and TAL 
modules were connected via linker L6 that was shown to support the highest level of 
activity of the zinc-finger recombinases (Gaj T 2013). (Figure 2-12) 
The protocol is followed by Golden Gate TALEN and TAL Effector Kit 1.0 
(Addgene) (Z. R. Cong L 2012, Streubel J 2012). 
A system developed by my colleagues in the laboratory allows us to easily 
convert the FL and TAL fusion genes from a prokaryotic expression vector (P33) to a 
eukaryotic expression vector (pog) by a simple cleavage, linkage, and transformation. 
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3.4 Experiments in mammalian cells 
Human embryonic kidney cell 293 [HEK-293](ATCC® CRL-1573™) were used 
to analysis the activity of the Flp variants. Cells were cultured in regular DMEM medium 
(Corning®).  
Polyfect(Qiagen®) or DNA-In  (Molecular Transfer®)was used for cell 
transfection. 
3.4.1 The construction of  reporter vector and expression vector 
Flp and Flp-TAL variants were expressed from the pOG100 vector, which is a 
derivative of pOG44 (Anderson, Voziyanova and Voziyanov 2012). The pTarget reporter 
vector is a derivative of the pDNA3 vector (Invitrogen). 
The reporter vectors for the integration experiments were based on the pcTD 
vector that is described in Anderson et al (Anderson, Voziyanova and Voziyanov 2012). 
The platform reporter pCMV-FL-DsRed-neo and the incoming reporter pFL-puro-2A-
EGFP, which were used in the integration experiments in HEK 293 cells, were generated 
as follows. The DsRed-neoR cassette from pIRES2-DsRed-Express (Clontech) was PCR 
amplified and subcloned into pcTD downstream from the CMV promoter to obtain 
pCMV-FL-DsRed-neo. FL sequence upstream of the DsRed-neoR cassette was 
introduced during the amplification of the cassette. The puroR gene from pCAGGS-Flpe-
puro (Addgene plasmid 20733) and the EGFP gene from pIRES2-EGFP (Clontech) were 
PCR-assembled into one gene through the connecting 2A peptide and cloned into pcTD 
downstream from the CMV promoter to obtain pCMV-FL-puro-2A-EGFP. FL sequence 
upstream of the puro-2A-EGFP gene was introduced during its amplification. The CMV 
promoter in this plasmid was then deleted to obtain pFL-puro-2A-EGFP. 
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For the experiments with the intact HEK 293 cells, the pCMV-FRT-puro-2A-
EGFP reporter was modified by cloning the PGK promoter from pDIRE25 (Addgene 
plasmid 26745) upstream of the promoterless hygroR gene.  
3.4.2 Construction of Platform Reporter Cell Lines 
HEK 293-FRT-DsRed-neo cell line was constructed by transfecting HEK 293 
cells with pCMV-FRT-DsRed-neo, propagating them in medium supplemented with 
neomycin (800 mg/l) and selecting for the red colonies. Several such colonies were 
expanded and tested for single integrated platform reporter vector by Southern blotting; 
the positive colonies were used in the integration experiments. 
3.4.3 Integration assays in human cells 
We first used the free reporter plasmid and expression plasmid to co-transfect the 
cells to determine the Flp variants’ basic activity in human cells. After initially 
confirming the activity of Flp variants, we used the model cells, which had integrated the 
test genes into the cells of the genome, to detect Flp variant’s activity. 0.5 ug DNA was 
transfected into a 70% confluence cell according to the protocol of the polyfect product . 
After 48 hours, the discolored cells were searched by fluorescence microscopy and 
recalled, placed in a 96-well plate, and the flora expanded until a sufficient amount (six-
well plate or 100 mm plate) was collected of the cells and further analysis of DNA was 
performed. 
The experiments to integrate pTarget into FL-61 and FL-71 were performed as 
follows. HEK-293 cells were co-transfected, in 24-well plates, with pTarget (0.4 µg) and 
the respective pOG100-Flp-TAL vector (1 µg). 48 hours post-transfection, 1/4 of the 
cells were transferred into 6-well plates containing EMEM medium supplemented with 
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hygromycin (550 mg/l). About 7 days later, individual red (FL-61 experiments) or green 
(FL-71 experiments) hygromycin resistant colonies were transferred into 48-well plates, 
expanded and analyzed by PCR and then sequenced. 
3.4.4 Deletion assays in human cells 
The experiments to delete the fragment of genome next to integrated pTarget were 
performed by transfecting the respective cells in 24-well plates with pOG100-Flp-
TAL/71 (2 µg). 48 hours post transfection, all cells were transferred into 6-well plates, 
allowed to become confluent, collected, and analyzed by PCR and sequencing. 
3.5 Other Methods 
Plasmid DNA was isolated using GeneJET Plasmid Miniprep Kit (Thermo). 
Amplification of the DNA fragments used for cloning was performed using Pfu-Ultra 
polymerase (Agilent Technologies). PCR analysis of the mammalian genomic DNA was 
performed using Taq polymerase (New England Biolabs). Genomic_ENREF_25 DNA 
from cultured mammalian cells was isolated using GeneJET Genomic DNA Purification 
Kit (Thermo). General genetic engineering experiments were performed as described in 







4.1 Genomic target-like sequences.  
For our experiments we chose three FRT-like sequences that are located upstream 
of the human δ-globin gene and within the δ-globin and β-globin genes: FL-61, FL-63, and 
FL-71, respectively, which are separated from each other by 2.7 kb and ~7.5 kb, 
respectively (Figure 2-5A and B). 
These FRT-like sequences, as well as other genomic FRT-like sequences, can have 
several potential upstream and downstream TAL recognition sequences since the 
requirements for the TAL recognition sequences are quite relaxed – the only major 
prerequisite is a thymine at the position N-1 of the sequence: 5’T (Lamb BM 2013). We 
reasoned that to be useful in targeting Flp-TAL recombinases to the desired FRT-like 
sequences and to be easily manageable from the technical point of view, the TAL module 
has to recognize the DNA sequence of 15-24 bp in length. We also reasoned that the TAL 
binding sequence should be separated from the recombinase binding element of the FRT-
like sequence by 3 to 12 base pairs to avoid steric clashes between the hybrid recombinase 
modules or their significant spatial separation. 
Additionally, we reasoned that the length of the TAL binding sequences should 
correlate with the degree of similarity between the Flp binding elements of the FRT-like 
sequence and that of FRT: the weaker the similarity, the longer the TAL recognition 
sequence. 
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Based on the above considerations, we decided to test the TAL biding sequences of 15 
bp in length (except for the upstream 24-bp TAL binding site for FL-71) that are separated 
from FL-61, FL-63, FL-71 by 4-5 bp (Figure 4- 2C). 
4.2 Evolution of Flp variants with strict and relaxed target specificity. 
Over the course of our research we evolved a number of Flp variants that recognize 
different genomic targets (e. a. Bolusani S 2006, Shultz JL 2011, L. F. Shah R 2015). In 
addition to unique mutations, these variants contain a group of mutations that are usually 
present in all variants. Most likely, these common mutations collectively relax the strict 
target specificity of Flp and allow it to recombine not only FRT but also FRT-like 
sequences. The unique mutations in these Flp variants either further relax or, in contrast, 
narrow the variant’s target specificity. 
The Flp variants that bear the common as well the unique mutations can be used to 
speed up the evolution of the Flp variants with target-specific or target-relaxed phenotypes 
if their genes are used as templates for generating shuffled variant libraries which can be 
screened to identify the desired target specificity. The pool of the template variant genes 
can be enhanced by including the library of the Flp genes that were randomized at codons 
55, 58 and 59 since the amino acids at these positions contact the first four base pairs of 
the Flp binding elements of FRT that were shown to be the most critical for the Flp-FRT 
recognition (Shultz JL 2011). 
Flp variants that are suitable for generating hybrid Flp-TAL recombinases, that is, those 
with relatively low activity and with strict or somewhat relaxed target specificity, can be 
evolved by one or two rounds of protein evolution using a pair of different but related 
recombination sequences: a genomic FRT-like sequence and FRT. We tested this evolution 
38 
approach using three recombining pairs: FL-61/FRT, FL-63/FRT, and FL-71/FRT, and 
then compared the activity of the evolved Flp variants on the FL-61, FL-63, and FL-71 
sequences. 
To identify Flp variants with the desired properties we designed a screening system 
that is composed of the inversion and deletion reporters that are used sequentially (Figure 
4-1 A and B). The reporter cassettes in these vectors are flanked by the pair of the 
recombination sites that are arranged in the head-to-head and head-to-tail orientations, 
respectively. The inversion and deletion reporters have different purposes. The inversion 
reporter is used to identify a large pool of Flp variants that are able to recombine both the 
FRT-like sequence and FRT; these variants are selected by amplifying the Flp variant genes 
in the inversion-positive configuration of the reporter (Figure 4-1 A). The deletion reporter 
is used to screen the inversion-positive library of the Flp variants that are sufficiently active 
to delete the reporter cassette in at least some vector molecules (Figure 4- 1 B). 
The screen of the library of the shuffled Flp variants that bear the desired set of 
mutations discussed above using the respective inversion and deletion reporters identified 
several Flp variants that were able to recombine the FL-61/FRT, FL-63/FRT, and FL-
71/FRT pairs with reasonable efficiency. The variants that demonstrated the highest 
activity on their respective recombination pairs were named FV61, FV63, and FV71 and 
tested for their ability to recombine all three FRT-like sequences to identify the variants 
with either strict or broad target specificity (Figure 4- 1D and E). 
FV61, FV63, and FV71 responded differently when they were challenged with the 
‘non-cognate’ FRT-like sequences (Figure 4- 1D and E). FV63 was the most specific and 
was able to efficiently recombine only the FL-63 sequence; some minor recombination 
39 
activity was seen on the FL-61 but the recombination activity on FL-71 was barely 
detectable. FV71 was the least specific and was able to recombine all three FRT-like 
sequences. FV61 was also able to recombine FL-61, FL-63, and FL-71, but we noticed 
abnormalities in its phenotype: the pale blue colonies in the experiments with all FRT-like 
sequences (Figure 4-1D) and the faint reporter bands in the FL-71 experiments (both 
unrecombined and recombined, Figure 4-1E); they apparently indicate that FV61 binds to 
DNA (or just to the FRT-like sequences) tighter than do FV63 and FV71. Off note, our 
evolution experiments sometimes generate Flp variants with the FV61-like phenotype. 
The mutational profile of FV61, FV63, and FV71 is shown in Figure 4- 3C. As 
anticipated, these Flp variants bear a group of common mutations: at positions 35, 45, 50, 
114, 295, 363. In addition, each variant has a set of unique mutations, some of which were 
seen before in other target-specific Flp variants (positions 44, 62, 130, 173, 176, 193, and 
324) while the other unique mutations are new (positions 3, 18, 75, 85, 157, 171, 213, and 
290). In addition, FV61 and FV63 had the same set of mutations at positions 55, 58, and 
59 which were different from that of FV71; the functional significance of this difference 
requires further analysis. We also noted that the profile of mutations in FV61, FV63, and 
FV71 is different from that of the Flp variants that were previously evolved to recombine 




4.3 Target-Specific Flp Variant Recombines FL-IL10A Sequence Pre-integrated  
To test whether target-specific Flp variants can recombine their cognate DNA 
sequences in mammalian genome, we chose well-characterized Flp variant FV7 (M. C. 
Bolusani S 2006) that recognizes FL-IL10A (Figure 2-5 B) located upstream of the 
human interleukin-10 gene. For these experiments, we generated a CHO cell line with 
FL-IL10A singly integrated into genome. 
A schematic of the assay to test the integration activity of FV7 is shown in Figure 
4-1 A. The FL-IL10A site in the pre-integrated platform reporter pCMV-IL10A-DsRed is 
located between the CMV promoter and the DsRed gene. The incoming reporter pIL10A-
EGFP bears the hybrid FRT/FL-IL10A site (Figure 4-2C) followed by the promoterless 
EGFP gene. Upon integration of the incoming reporter into the FL-IL10A site, the EGFP 
gene is transferred under the control of the CMV promoter, thus preventing the DsRed 
gene from being expressed. This integration event can be detected by the appearance of 
green, non-red cells. 
Figure 4-1: Evolution of Flp-TAL recombinases. (A) Inversion assay. The reporter bears 
an inversion cassette flanked by the recombination targets in the head-to-head orientation: 
FL-61, FL-63, or FL-71 (marked as RT) and FRT* with the spacer either from FL-61, FL-
63, or FL-71, respectively. Upon expression of a recombination competent Flp variant, the 
cassette is inverted so the gene that encodes this variant can be amplified. (B) Deletion 
assay. The deletion reporter bears the lacZα cassette flanked by the recombination targets
in the head-to-tail orientation. If a Flp variant is able to delete the cassette, the resulting 
bacterial cells will form white colonies when plated on the X-gal containing plates. (C) 
Mutations in FV61, FV63, and FV71. (D) Activity of FV61, FV63, and FV71 on the FL-
61, FL-63, and FL-71 substrates. The assays were performed using the deletion reporter. 
(E) Electrophoregram of the uniquely digested vector DNA isolated from the pooled 
colonies in the respective plates shown in D. Ctr, control vectors; EV, expression vector; 
RV, reporter vector; EV + RV, Flpe expression vector and the deletion reporter that bears 
the FRT flanked lacZα cassette, which was completely deleted; M, DNA ladder. 
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The integration activity of FV7 was tested by transfecting the reporter cells with 
the incoming reporter and the FV7 expression vector. The experiments were performed in 
6-well plates. 48 hours after transfection, the cells were expanded and screened for the 
groups of green cells (Figure 4-2B). Only these groups and not individual green cells 
were counted as productive integration events. Based on the number of groups of green 
cells and the efficiency of the control transfection of an EGFP-expressing reporter similar 
in size to pIL10A-EGFP, we estimated the efficiency of the FV7-mediated integration 
into FL-IL10A as a fraction of the transfected cells. On average, in the one-sixth of the 
expanded transfected cells we observed 17 integration-positive green, non-red colonies 
(Figure 4-2 C). This number corresponded to about 0.1% of the transfected cells (Figure 
4-2 C). In the expanded cells, in addition to the green, non-red cells, we also noticed rare 
green/red colonies: on average, 1 colony per plate of the expanded cells; these colonies 
were not analyzed. In the control experiments performed with the incoming reporter 
alone, no green or green/red colonies were observed. 
We expanded and analyzed 10 green, non-red colonies obtained as described 
above. The integration events in all these colonies were confirmed by PCR (Figure 4-2 




Figure 4-2: FV7-mediated integration of a reporter into FL-IL10A pre-integrated into the 
CHO genome. (A) Schematic outline of the integration assay. The horizontal blue and red 
bars in panels (A) and (D) schematically represent the PCR products at the left junction 
[LJ] and the right junction [RJ] of the integration product and the control PCR product of 
the platform reporter [C2]. (B) Green colonies are formed after the transfected cells are 
split and expanded. (C) The efficiency of the FV7-dependent integration is represented 
by the green bar that shows the mean value of three experiments; the error bar indicates 
standard deviation. (D) PCR analyses of a typical expanded green colony. LJ and C1 
lanes show the results of the PCR analysis of the green cells and the original platform 
cell, respectively, using the same primers that anneal on the CMV promoter and the 
EGFP gene. RJ and C2, the PCR analysis of the green cells and the control platform cells 
using the primers that anneal on the vector backbone and the DsRed gene. M, DNA 
marker. (E) Representative sequencing snapshots of the recombination site regions in the 
diagnostic PCR products LJ and RJ (panel D). The schematics of the recombination sites 
and the surrounding sequences are shown above the sequencing snapshots. 
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4.4 Flp-TAL recombinase architecture.  
The mode of binding of the Flp recombinase to its native recognition sequence, Flp 
Recombination Target, or FRT, specifies the mode of binding of the hybrid Flp-TAL 
recombinase to its target (Figure 2-12A): the Flp module binds to the inner segments of the 
target sequence, which constitute the actual FRT-like sequence, while the TAL module 
binds the outer segments of the target sequence. 
The analysis of the Flp/DNA and the TAL DBD/DNA complexes (Chen, et al 2000, 
Mak AN 2012) shows that, in principle, the TAL module can be fused to either the C-
terminus or to the N-terminus of the module Flp, thus creating two hybrid recombinase 
architectures: Flp-TAL and TAL-Flp (Figure 2-12B). In principle, both Flp-TAL and TAL-
Flp are capable of binding to the head-to-tail and the tail-to-tail arrangements of the target 
sequences provided the length of the linker that connects the modules is sufficiently long 
(Figure 2-12B). However, in the compact modes of the Flp-TAL and TAL-Flp architectures 
(that is, when the linker that connects the modules is short) Flp-TAL is able to bind to the 
‘convenient’ head-to-tail arrangement of the target sequence while TAL-Flp can bind to 
the ‘inconvenient' tail-to-tail arrangements of the target sequences (Figure 2-12B). The 
‘convenience’ here is the property of the target sequence arrangement that describes (e. a. 
Miller JC 2011) how easy it is to increase the length of the DNA sequence to which the 
TAL module binds and (e. a. Cong L 2013) how easy it is to avoid steric clashes between 
the hybrid recombinase modules without changing the length of the inter-modular linker 
when the TAL modules with different lengths of the C-terminal domain are used. 
Considering all the features of the hybrid recombinases architectures, we decided to 
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proceed with the Flp-TAL architecture and the head-to-tail organization of the target 
sequence (Figure 2-12B). 
In the Flp-TAL design we utilized the TAL DNA-binding domain and the inter-
modular linker that were proven in other hybrid enzymes (Figure 2-12C). The full-size Flp 
recombinase variant was fused to the TAL core DNA-binding domain that starts at the 
position +152 (Δ152 truncation of the N-terminal segment of the TAL effector) and ends 
at the position +95 of the C-terminal segment of TAL effector (e. a. Miller JC 2011). The 
Flp and TAL modules were connected via linker L6 that was shown to support the highest 
level of activity of the zinc-finger recombinases (Akopian A 2003). 
4.5 Flp-TAL variants can integrate a reporter into the desired locations in the 
human genome. 
To test whether Flp-TAL recombinases are capable of targeting FRT-like sequences 
in their native environment, we fused the FV61, FV63, and FV71 variants with their 
respective TAL modules (Figures 2-12A and 2-5C). Since the TAL modules in the Flp-
TAL recombinase have to be specific for both upstream and downstream TAL recognition 
sequences of the FRT-like sequence, two Flp-TAL variants for each fusion recombinase 
were engineered: Flp-TAL(L) and Flp-TAL(R), Figure 2-12A. For the sake of simplicity, 
the left and the right Flp-TAL variants of FV61, FV63, and FV71 will be collectively called 
FV61-TAL, FV63-TAL, and FV71-TAL, respectively. 
The targeting activity of the hybrid Flp-TAL recombinases was analyzed via 
integration and deletion assays (Figures. 4-3 and 4-4). The schematic of the integration 
assay is shown in Figure 4- 3A. The reporter vector pTarget bears three transcriptional units 
that express EGFP, hygromycin B phosphotransferase gene (hygroR), and DsRed. In this 
46 
reporter, the hybrid FRT/FL-61 (or FRT/FL-63) site is located between the CMV promoter 
and the EGFP gene while the hybrid FRT/FL-71 site is positioned between the EF1α 
promoter and the DsRed gene. 
If FV61-TAL (or FV63-TAL) integrates pTarget into the native FL-61 (or FL-63) 
sequence, the EGFP gene loses its promoter and thus cannot be expressed. The resultant 
cells should be therefore red and not green (Figure 4- 3A). Alternatively, if FV71-TAL is 
capable of integrating pTarget into the native FL-71, the DsRed gene loses its promoter 
and cannot be expressed. The resultant cells should be just green (Figure 4-3A). 
To test the integration activity of the Flp-TAL recombinases, we co-transfected 
HEK293 cells with the pTarget reporter and the vector that express either FV61-TAL, 
FV63-TAL, or FV71-TAL. 48 hours post-transfection, 1/10 of the cells were transferred 
into medium supplemented with hygromycin and incubated for about 10 days until the 
hygroR colonies are formed. Four types of colonies were observed: with no color, green 
and red, just green, and just red. We did not note apparent differences in the ratios of these 
colony types in the experiments with FV61-TAL, FV63-TAL, and FV71-TAL. 
To determine if the Flp-TAL recombinases are capable of integrating the reporter into 
the desired FRT-like sequences, the hygromycin resistant colonies were pooled and their 
genomic DNA isolated and subjected to the PCR analysis, which confirmed the correct 
integration events (Figure 4-3B). 
Importantly, the control experiments with the ‘plain’ Flp variants FV61, FV63, and 
FV71 did not yield detectable integration of the reporter into the respective FRT-like 
sequences. 
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To determine the efficiency of integration, we performed a series of integration 
experiments as described above but instead of pooling all hygromycin resistance colonies 
we expanded only either just red colonies (FV61-TAL and FV63-TAL experiments) or just 
green colonies (FV71-TAL experiments) and subjected them to the PCR analysis. These 
experiments revealed that the hybrid recombinases integrated the reporter vector, on 







4.6 FV71 can be fused to the TAL modules with different target specificity to 
recombine different FRT-like sequences in the human genome.  
We next tested whether FV71, which was able to recombine different FRT-like 
sequences in bacteria (Figure 4-3E and D), could also recombine these sequences in their 
native genome environment. For this, we fused FV71 with the respective TAL modules 
that are specific for either FL-61 or FL-63 (Figure 2-5C) to obtain the FV71-TAL61 and 
FV71-TAL63 variants, respectively. We then performed the integration experiments as 
described in the previous section and found that FV71-TAL61 and FV71-TAL63 were able 
to target FL-61 and FL-63 as efficiently as did FV61-TAL and FV63-TAL (Figure 4-4). 
In parallel, we tested if FV61, which showed an apparent tight binding phenotype in 
bacterial cells (Figure 4-3E and D), was able to target FL-71 if fused to the respective TAL 
module. Despite extensive experimenting we were unable to detect FV61-TAL71-
mediated integration of the reporter vector into FL-71. 
 
Figure 4-3: Flp-TAL variants can target FL61, FL63, and FL71 in unmodified HEK-293 
cells. (A) Schematics of the integration assays. The reporter can be integrated either into 
FL-61, FL-63, or FL-71 depending on the specificity of the Flp-TAL variant. Upon 
integration of pTarget into FL-61 or FL-63 the resultant cells become hygromycin resistant 
and red, while if integrated into FL-71, the cells become hygromycin resistant and green 
(images of the individual expanded hygroR/red and hygroR/green colonies are shown as 
examples). LJ and RJ show the locations of the diagnostic PCR products at the left and 
right junctions of the integrated reporter and genomic DNA. (B) PCR analysis of the pooled 
hygroR colonies. LJ, RJ, the PCR analysis of the left and right junctions of pTarget 
integrated into the respective genomic sequences; M, DNA ladder. (C), (D), and (E) 
Sequencing of the integration-specific PCR products LJ and RJ of pTarget integrated into 
FL-61, FL-63, and FL-71, respectively, confirmed their identity. 
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4.7 Flp-TAL recombinases can delete genome fragments.  
Finally, we tested the ability of the Flp-TAL recombinases to delete large genome 
fragments. For this we utilized the property of the pTarget vector to bear two different FRT-
like sequences (Figure 4-4 A). Upon integration of the vector into one of the respective 
genomic FRT-like sequences, the other vector-borne FRT-like sequence can be used to 
delete a DNA fragment that is located between this sequence and the corresponding 
genomic FRT-like sequence (Figure 4-4A). 
In the deletion assays we used the expanded integration-positive red cells that were 
obtained in the FV61-TAL integration experiments (Figure 4-4). These cells were 
transfected with the vector that expresses the FV71-TAL recombinase, then expanded and 
subjected to the PCR analysis to assess the ratio of the cells, in which the 14.7 kb DNA 
fragment was deleted. The analysis of the sequentially diluted genomic DNA revealed that 




Figure 4-4: Flp-TAL variants can delete a genome fragment. (A) Schematic of the deletion 
assay. Upon expression of FV71-TAL, the DNA fragment that is located between two FL-
71 sequences and that contains part of the reporter and genomic DNA gets deleted. (B) 
PCR analysis of the FV71-TAL treated cells which bear pTarget integrated into FL-61. LJ 
and RJ are the left and right junctions of the reporter and the genomic DNA. CLJ and CRJ 
control PCR analyses of the original cells using the same primers as in lanes LJ and RJ; M, 









The successful use of Flp variants as a means of gene therapy depends to a large 
extent on the recombination activity in human cells. We have tried to express activity of 
the evolved recombinase variants in a variety of different cells with FV7 to test if there 
was any difference. A375(Human malignant melanoma), 293A(subclone of the 293 Cell 
Line), CHO-TD1(Chinese hamster ovary cell), A549(Adenocarcinomic human alveolar 
basal epithelial cells), and NIH 3t3(Embryonic mouse fibroblast) cell lines were tested. 
Among them, 293A is the easiest to transfect, and the CHO cells show the highest 
recombination activity.  The recombination reaction can be easily  performed in CHO cell 
lines. In human cells, the activity is not as high as CHO cell lines. The recombination 
activity in 293 cells is acceptable. We have great hope in 549 cells, because the cell line 
can theoretically express hemoglobin, at least on the RNA level. But our tests show that, 
Flp variants are very inactive in both 549 and 375 cell lines. Even the deletion reactions 
are difficult to observe in 549 and 375 cell lines. 
A prerequisite for recombination reaction is the completion of transfection. For 
RMCD rearrangement, it is not an easy task to transfect at least three plasmids 
(templates, two-stage expression plasmids) into the cells synchronously and to ensure 
their activity. Therefore, the optimization of transfection is essential for this experiment. 
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A paradox is that too high a transfection rate has a somewhat negative side for 
recombination reactions.  
Excessive free-form reporting plasmids can cause significant problems when 
editing cellular genomic DNA. We must continually culture the cells for multiple 
generations and, by sometimes being selected by antibiotics, remove those cells which 
carry the episomal plasmid that contains the reporter gene. Even so, the interference of 
the episomal reporting plasmid with the DNA detection results cannot be completely 
eradicated. We have also tried to add a gene which induces cell suicide in the reporter 
plasmid to ensure that suicide genes were activated on plasmids that were not integrated 
in the genome. The experiment ended with the complete destruction of the cells. Besides, 
the problem of fluorescent fading during the test also troubled us. We believe that the use 
of different fluorescent genes or the use of specific equipment such as FAC will 
significantly help the experiment.  
Since shearing and integration are inherently reversible reactions, sometimes after 
the reporter plasmids have been integrated into the genomic DNA, there is a risk of  the 
reporter gene being re-cut out by the same recombination reaction. To keep high 
efficiency, the concentration of working recombinase should be high. To reduce the 
reverse reaction of shearing, the concentration of recombinase should be as low as 
possible. The best working concentration of recombinase transfection still needs to be 
tested by experiments. 
The activity of the Flp variants is not very satisfactory in human cells. We suspect 
the reason is that the DNA of eukaryotes is always under high packaging. We used 
CRISPR/CAS9 and some molecular factors which induce cells to become iPSC, so the 
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DNA package opens. Insulin has been tried for the same purpose. We have discovered 
that sometimes insulin can even cause recombination reactions in A375 cell lines, but this 
result is not stable and is not repeatable. TALEN as nucleases are also used to cut DNA 
in hopes of opening the package of genomic DNA, but the effect is not apparent. 
It can be seen from the results that the fusion of TAL domain considerably 
increases the activity of Flp variants. The addition of the NLS sequence can increase the 
activity of Flp variant 4-10 fold. A suitable TAL structure will increase activity by nearly 
10 times more. However, the "appropriate" TAL can only be obtained through testing. 
The length of the TAL domain, and the distance between the TAL-binding site and the 
recombinase domain can also effect Flp variants’ activity. Some Flp variants prefer an 
RVD of 15 or 18 nucleotides. For some Flp variants, the ultra-long 24 RVD has the most 
activity. Some Flp variants, even 12-length RVD, can achieve a good reinforcement.  
For the same locus of Flp variants, the TAL domain blended on the left, but the 
right sides were completely different and seemed to be unrelated. We hypothesize that the 
fusion of TAL and Flp variants restrict Flp variants in site binding. But it is not easy to 
find a particular law for this restriction. 
The best performing Flp variants in bacteria often perform badly in eukaryotic 
cells. Those Flp variants which play well in eukaryotic cells often have up to 80% of cell 
discoloration in bacterial colony screening. For those Flp variants with a discoloration 
rate of more than 90%, the activity is entirely lower than the variants of only 80% or 
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